Miraculins Files Pre-submission Documentation with the USFDA for its Scout DS® Diabetes Testing Technology

December 23, 2013

WINNIPEG, Manitoba – December 23, 2013 - Miraculins Inc.(TSX-V:MOM), (”Miraculins” or the “Company”) a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, is pleased to announce today that it has filed pre-submission documentation with the USFDA (United States Food and Drug Administration) for its Scout DS® System towards securing its ultimate marketing clearance in the United States.

The Scout DS® is the world’s first non-invasive and highly-sensitive test designed to measure diabetes related biomarkers in the skin. It does not require a blood draw or fasting and generates a result in as little as 80 seconds. The Scout DS® uses visible light to measure the optical signature of fluorescent biomarkers in the skin, the accumulation of which are accelerated by abnormal blood sugar levels and oxidative stress.

The pre-submission documentation filing is the first formal step by Miraculins in establishing a clinical and regulatory plan for the regulatory clearance of theScout DS® in the United States. Based on feedback from this cooperative process with the FDA, Miraculins will develop appropriate study protocols in support of FDA marketing clearance.

Click here for the article

Share This Story


“This is an important milestone for our Company as we begin to implement our plans for the Scout DS® globally,” said Christopher J. Moreau, President and Chief Executive Officer for Miraculins Inc. “We look forward to working cooperatively with the FDA as the new owners of the technology and bringing new energy and resources towards establishing a pathway for Scout DS® marketing clearance in the important U.S. market, where we believe the measurement of diabetes related biomarkers in the skin can have a considerable impact on the fight against the type 2 diabetes epidemic.”